Jamshid Motalebzadeh

Jamshid Motalebzadeh

Higher Degree by Research Candidate

Adelaide Medical School

Faculty of Health and Medical Sciences

With a broad range of research experience in bioinformatics, genetics, epigenetics, metabolomics, and molecular biology, Jamshid is eager to find new ways to alleviate cancer symptoms based on molecular-targeted therapies to elevate the quality of life for cancer patients. His research goes deeper into metabolomics and epigenetics, studying how gene expression changes by different factors and influences cancer. So far, he has identified key metabolites, transcription factors, and miRNAs that regulate genes involved in cancer, particularly in breast and gastrointestinal cancer.

His interdisciplinary approach, combining bioinformatics, metabolomics, genetics, and molecular biology, aims to uncover new therapeutic targets and improve cancer treatment outcomes. His work is characterized by a strong emphasis on both basic and translational research, bridging the gap between in-silico, in-vitro, in-vivo, and clinical applications.

  • Journals
    Year Citation
    2022 Motalebzadeh, J., & Eskandari, E. (2022). Comprehensive analysis of DRAIC and TP53TG1 in breast cancer luminal subtypes through the construction of lncRNAs regulatory model. Breast Cancer, 29(6), 1050-1066.
    DOI Scopus2 Europe PMC1
    2021 Shabani, S., Khayer, N., Motalebzadeh, J., Zadeh, T. M., & Mahjoubi, F. (2021). Characterization of pathways involved in colorectal cancer using real-time RT-PCR gene expression data. Gastroenterology and Hepatology from Bed to Bench, 14(2), 123-131.
    DOI Scopus7
    2021 Motalebzadeh, J., & Eskandari, E. (2021). Transcription Factors Linked to the Molecular Signatures in the Development of HCC on a Cirrhotic Background.
    DOI
    2021 Motalebzadeh, J., & Eskandari, E. (2021). Transcription factors linked to the molecular signatures in the development of hepatocellular carcinoma on a cirrhotic background. Medical Oncology, 38(10), 12 pages.
    DOI Scopus3 WoS3 Europe PMC2
    2020 Motalebzadeh, J., & Eskandari, E. (2020). Syntrophin beta 1 (SNTB1): Candidate as a new marker for colorectal cancer metastasis. Gene Reports, 20, 7 pages.
    DOI Scopus3 WoS2
    2019 Eskandari, E., & Motalebzadeh, J. (2019). Transcriptomics-based screening of molecular signatures associated with patients overall survival and their key regulators in subtypes of breast cancer. Cancer Genetics, 239, 62-74.
    DOI Scopus7 WoS6 Europe PMC8
    2018 Motalebzadeh, J., Shabani, S., Rezayati, S., Shakournia, N., Mirzaei, R., Mahjoubi, B., . . . Mahjoubi, F. (2018). Prognostic value of FBXO39 and ETS-1 but not BMI-1 in Iranian colorectal cancer patients. Asian Pacific Journal of Cancer Prevention, 19(5), 1357-1362.
    DOI Scopus6 Europe PMC2
    2018 Taheri, M., Motalebzadeh, J., & Mahjoubi, F. (2018). Expression of LRP gene in breast cancer patients correlated with MRP1 as two independent predictive biomarkers in breast cancer. Asian Pacific Journal of Cancer Prevention, 19(11), 3111-3115.
    DOI Scopus5 Europe PMC3
    2018 Eskandari, E., Mahjoubi, F., & Motalebzadeh, J. (2018). An integrated study on TFs and miRNAs in colorectal cancer metastasis and evaluation of three co-regulated candidate genes as prognostic markers. Gene, 679, 150-159.
    DOI Scopus20 WoS16 Europe PMC18
    2017 Motalebzadeh, J., Mahjoubi, F., Nafissi, N., Hashemian, M., Taheri, M., & Hosseinpour, Y. (2017). FBLN-4 and BCRP genes as two prognostic markers are downregulated in breast cancer tissue. Cancer Biomarkers, 19(1), 51-55.
    DOI Scopus7 WoS4 Europe PMC5

  • Conference Papers
    Year Citation
    2017 Motalebzadeh, J., Mahjoubi, F., Eskandari, E., Rezayati, S., Shakournia, N., & Ayoubi, H. A. (2017). FBXO39, ETS-1 and H3F3B genes as three candidates for prognosis of colorectal cancer metastasis. In EUROPEAN JOURNAL OF CANCER Vol. 72 (pp. S137). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD.
    DOI

More than five years experience in bioinformatics and genetics.

Connect With Me
External Profiles